Back to top

Analyst Blog

Zacks Equity Research

Achillion, J&J HCV Triple Combination Drug Data Presented


Trades from $3
Achillion Pharmaceuticals, Inc. (ACHN - Analyst Report) presented updated interim results from a phase II study on a triple combination of AL-335, odalasvir (also known as ACH-3102) and Johnson & Johnson’s (JNJ - Analyst Report) Olysio (simeprevir) at the European Association for the Study of the Liver (EASL) Special Conference in Paris, France.
The phase IIa study was designed to determine the pharmacokinetics, efficacy and safety of odalasvir and AL-335, with or without simeprevirfor, in the treatment of patients suffering from genotype 1 chronic hepatitis C virus (HCV) infection.
In Jun 2015, Achillion out-licensed its HCV portfolio to Johnson & Johnson. Under the agreement, Johnson & Johnson has global rights to develop and commercialize one or more of Achillion's lead HCV candidates, including ACH-3102, ACH-3422 and sovaprevir.
The phase II study is being conducted by Alios BioPharma, Inc., part of a Johnson & Johnson subsidiary, Janssen. Note that AL-335 is a nucleotide-based HCV NS5B polymerase inhibitor, odalasvir is an HCV NS5A inhibitor and Olysio is an HCV NS3/4A protease inhibitor.
The study showed that 100% of the patients on the six-week arm as well as the eight-week arm, who were treated with the triple combination of once-daily (QD) AL-335 800mg and simeprevir (SMV) 75mg with 50mg every other day (QOD) of ODV, achieved a sustained viral response 12 weeks after the completion of treatment (SVR12).
According to the company’s press release, almost 150 million people are infected with HCV worldwide, including approximately 3 million people in the U.S. This provides a huge potential market for the HCV triple combination globally.
Achillion’s collaboration with Johnson & Johnson for the HCV portfolio makes sense given the latter’s expertise in development and commercialization capabilities. Moreover, the deal could see Achillion receiving up to $1.1 billion in the form of development, regulatory and sales milestone payments, apart from a separate equity investment. Achillion is also entitled to receive tiered royalties in the mid teens to low twenties on future worldwide sales. All development and commercialization costs will be borne by Johnson & Johnson.
Zacks Rank & Key Picks

Achillion currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in health care sector include Anika Therapeutics Inc. (ANIK - Snapshot Report) and ANI Pharmaceuticals, Inc. (ANIP - Snapshot Report) . Both the stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Anika Therapeutics’ earnings estimates for 2016 and 2017 were up a respective 12.6% and 14% over the last 60 days. The company has recorded a positive earnings surprise in each of the last four quarters with an average beat of 42.19%. Its share price has jumped 23.2% year to date.
ANI Pharmaceuticals witnessed an increase of 9.5% and 4.7% in its earnings estimates for 2016 and 2017, respectively, in the last 60 days. It has beaten earnings estimates twice in the last four quarters, bringing the average positive surprise to 46.85%. The company’s share price has surged 51.2% year to date.

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>